ERBB2 and breast cancer: One of the main obstacles in the treatment of breast cancer is poor response to chemotherapeutic agents and anti-hormonal treatment in 1/3 of breast cancer patients due to lack of expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 which are classified as triple negative patients [4].